Advertisement
Research Article| Volume 10, ISSUE 1, P1-37, March 1990

Cancer Markers of the 1990s: Comparison of the New Generation of Markers Defined by Monoclonal Antibodies and Oncogene Probes to Prototypic Markers

  • Stewart Sell
    Correspondence
    Address reprint requests to: Stewart Sell, MD, Department of Pathology and Laboratory Medicine, University of Texas Medical School at Houston, P.O. Box 20708, Houston, TX 77225
    Affiliations
    Professor, Department of Pathology and Laboratory Medicine, University of Texas Medical School at Houston, Houston, Texas.
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30580-8
Cancer Markers of the 1990s: Comparison of the New Generation of Markers Defined by Monoclonal Antibodies and Oncogene Probes to Prototypic Markers
Previous ArticlePreface
Next ArticleTumor Markers in Endocrine Malignancies
      This paper is only available as a PDF. To read, Please Download here.
      Markers found in the blood of cancer patients may be used to make the diagnosis of cancer, determine the prognosis of a patient with cancer, and monitor the effects of therapy. In this review, the results using the prototype markers—monoclonal immunoglobulins, al-phafetoprotein, and carcinoembryonic antigen—are compared with those found with a number of more recently identified markers detected by monoclonal antibodies and oncogene products detected immunologically or by “anti-sense” probes. Although a “magic marker” for cancer has not been found, the systematic application of the appropriate set of markers for a given patient can add vital information that is not obtainable by other means.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Abelev G.I.
        Production of embryonal serum γ-globulin by hepatomas: Review of experimental and clinical data.
        Cancer Res. 1968; 28: 1344
        • Akerman M.
        • Barandt L.
        • Johnson A.
        • et al.
        Mitotic activity in non-Hodgkin’s lymphoma: Relation to the Kiel classification and to prognosis.
        Br J Cancer. 1987; 55: 219
        • Alitalo K.
        • Koskinen P.
        • Makela T.P.
        • et al.
        myc Oncogenes: Activation and amplification.
        Biochemica Biophys Acta. 1987; 907: 1
        • Arnaud J.P.
        • Koehl C.
        • Adloff M.
        Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma.
        Dis Colon Rectum. 1980; 23: 141
        • Bartram C.R.
        Oncogenes: Clues to carcinogenesis.
        Eur J Pediatr. 1984; 141: 134
        • Bence-Jones H.
        Papers on chemical pathology Lecture III..
        Lancet. 1847; 2: 269
        • Berger M.S.
        • Locher G.W.
        • Saurer S.
        • et al.
        Correlation of c-erb B-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
        Cancer Res. 1988; 48: 1238
        • Bhargava A.K.
        • Lele S.B.
        • O’Donnell A.
        • et al.
        Mutiple tumor markers in monitoring of ovarian carcinoma.
        J Tumor Marker Oncol. 1988; 3: 379
        • Bjorklund B.
        Overview of TPA: Specificity, immunochemistry and biological basis.
        in: Peters H. Protides Biol Fluids Proc. 31. Pergamon Press, New York1983: 425
        • Bombardieri E.
        • Colombo A.
        • Gion M.
        A preliminary evaluation of the tissue and serum levels of MCA, a new tumor-associated antigen of breast cancer.
        Tumor Diag Ther. 1988; 9: 39
        • Bradshaw T.K.
        Cell transformation: The role of oncogenes and growth factors.
        Mutagenesis. 1986; 1: 91
        • Browning M.
        • McFarlane P.
        • Horobin J.
        • et al.
        Evaluation of the comparative clinical utility of CA 15-3 and mucinous carcinoma-associated antigen (MCA) in the management of breast carcinoma.
        Ann Clin Biochem. 1988; 25 (Suppl)
        • Caravatti M.
        Biochemistry and quantification of MCA in serum.
        Tumor Diag Ther. 1988; 9: 39
        • Chata I.F.
        Use of serial CEA assay in detecting relapses in breast cancer involving high risk of metastasis.
        Eur J Cancer. 1980; 17: 233
        • Chen D.S.
        • Sung J.L.
        Serum alpha-fetoprotein in hepatocellular carcinoma.
        Cancer. 1977; 40: 779
        • Cohen J.A.
        • Weiner D.B.
        • More K.F.
        • et al.
        Expression pattern of the neu (NGL) gene encoded growth factor receptor protein (pl85neu) in normal and transformed epithelial tissues of the digestive tract.
        Oncogene. 1989; 4: 81
        • Colcher D.
        • Carrauillo J.A.
        • et al.
        Radiolabeled monoclonal antibody B72.3: Localization in metastatic lesions of colorectal cancer patients.
        Nucl Med Biol. 1987; 14: 251
        • Crescenzi M.
        • Seto M.
        • Herzig G.P.
        • et al.
        Thermostable DNA polymerase chain amplification of t(14;18) chromosomal breakpoints and detection of minimal residual disease.
        Proc Natl Acad Sci. 1988; 85: 4869
        • Davis H.M.
        • Zurawski V.R.
        • Bast R.C.
        • et al.
        Characterization of the CA 125 antigen associated with epithelial ovarian carcinomas.
        Cancer Res. 1986; 46: 6143
        • Dhokia B.
        • Pectasides D.
        • Epenetos A.A.
        • et al.
        Serum levels of c-myc and c-ras oncogene products in normal subjects and in patients with neoplastic and non-neoplastic conditions.
        Int J Biol Markers. 1986; 1: 29
        • Duesberg P.
        Cancer genes: Rare recombinants instead of activated oncogenes (a review.
        Proc Natl Acad Sci USA. 1987; 84: 2117
        • Durie B.G.M.
        • Salmon S.E.
        Cellular kinetics, staging and immunoglobulin synthesis in mutiple myeloma.
        Annu Rev Med. 1975; 26: 183
        • Edelman G.M.
        • Poulik M.D.
        Studies on the structural units of γ-globulin.
        J Exp Med. 1961; 113: 861
        • Endo K.
        • Matsuoka Y.
        • Nakashima T.
        • et al.
        Development of a new sensitive immunoradiometric assay for CA 125: Mixed use of two monoclonal antibodies reactive with separate epitopes.
        J Tumor Marker Oncol. 1988; 3: 65
        • Feizi T.
        Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are oncodevelopmental antigens.
        Nature. 1985; 314: 53
        • Fletcher R.H.
        Carcinoembryonic antigen.
        Ann Intern Med. 1986; 104: 66
        • Frebourg T.
        • Bercoff E.
        • Manchon N.
        • et al.
        The evaluation of CA 19-9 antigen levels in the early detection of pancreatic cancer.
        Cancer. 1988; 62: 2287
        • Freeman A.S.
        • Boyd A.W.
        • Bieber F.R.
        • et al.
        Normal cellular counterparts of B-cell chronic lymphocytic leukemia.
        Blood. 1987; 70: 418
        • Frizzera G.
        • Hanto D.W.
        • Gajl-Peczalska K.J.
        • et al.
        Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients.
        Cancer Res. 1981; 41: 4262
        • Garrett C.T.
        Oncogenes.
        Clin Chem Acta. 1986; 156: 1
        • Gerdes J.
        • Schwab U.
        • Lemke H.
        • et al.
        Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.
        Int J Cancer. 1983; 31: 13
        • Giuffre L.
        • Isler P.
        • Schreyer M.
        • et al.
        Melanoma-associated differentiation antigens: Investigation with monoclonal antibodies.
        Eur J Cancer Clin Oncol. 1988; 24: 51
        • Gold D.V.
        • Mattes M.J.
        Monoclonal antibody B72.3 reacts with a core region structure of O-linked carbohydrates.
        Tumor Biol. 1988; 9: 137
        • Gold P.
        • Freeman S.O.
        Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques.
        J Exp Med. 1965; 121: 439
        • Grogan T.M.
        • Lippman S.M.
        • Spier C.M.
        • et al.
        Independent prognostic significance of nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67.
        Blood. 1988; 71: 1157
        • Haglund C.
        • Kuusela P.
        • Jalanko P.
        • et al.
        Serum CA-50 as a tumor marker in pancreatic cancer: A comparison with CA 19-9.
        Int J Cancer. 1987; 39: 477
        • Haglund C.
        • Roberts P.J.
        • Kuusela P.
        • et al.
        Evaluation of CA 19-9 as a serum tumor marker in pancreatic cancer.
        Br J Cancer. 1986; 53: 197
        • Hakomori S.I.
        Tumor-associated glycolipid antigens, their metabolism and organization.
        Chem Physics Lipids. 1986; 42: 209
        • Hall P.A.
        • Richards M.A.
        • Gregory W.M.
        • et al.
        The prognostic value of Ki-67 immunostaining in non-Hodgkin’s lymphoma.
        J Pathol. 1988; 154: 223
        • Hanto D.W.
        • Frizzer G.
        • Purtilo D.T.
        • et al.
        Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus.
        Cancer Res. 1984; 41: 4253
        • Herlyn M.
        • Koprowski H.
        Melanoma antigens: Immunological and biological characterization and clinical significance.
        Ann Rev Immunol. 1988; 6: 283
        • Herlyn M.
        • Sears H.F.
        • Steplewski Z.
        • et al.
        Monoclonal antibody detection of a circulating tumor-associated antigen in sera of patients with colorectal, gastric and pancreatic carcinoma.
        J Clin Immunol. 1982; 2: 135
        • Heywars W.L.
        • Lanier A.P.
        • McMahon B.J.
        • et al.
        Early detection of primary hepatocellu lar carcinoma.
        JAMA. 1985; 254: 3092
        • Hilkens J.
        • et al.
        Monoclonal antibodies against human milk fat globule membrane detecting differentiation antigens of the mammary gland and its tumors.
        Int J Cancer. 1984; 34: 197
        • Inoue M.
        • Inoue Y.
        • Hiramatsu K.
        • et al.
        The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.
        Cancer. 1985; 55: 2618
        • Johnson V.G.
        • Schlom J.
        • et al.
        Analysis of human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.
        Cancer Res. 1986; 46: 850
        • Kamahara M.
        • Terasaki P.
        • Chia P.
        • et al.
        Use of four monoclonal antibodies to detect tumor markers.
        Cancer. 1986; 58: 2008
        • Kawasaki E.S.
        • Clark S.S.
        • Coyne M.Y.
        • et al.
        Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.
        Proc Natl Acad Sci USA. 1988; 85: 5698
        • Klein G.
        • Klein E.
        Conditioned tumorigenicity of activated oncogenes.
        Cancer Res. 1986; 46: 3211
        • Kohler H.
        • Millstein C.
        Continuous cultures of fused cells secreting antibody of pre defined specificity.
        Nature. 1975; 256: 495
        • Kufe D.
        • et al.
        Differential reactivity of a novel monoclonal antibody (DF 3) with human malignant versus benign breast tumors.
        Hybridoma. 1984; 3: 223
        • Landegren U.
        • Kaiser R.
        • Caskey T.
        • Hood L.
        DNA diagnostic-molecular techniques and automation.
        Science. 1988; 243: 229
        • Lee M-S
        • Chang K-S
        • Cabanillas T.
        • et al.
        Detection of minimal residual cells carrying the T(14;18) by DNA sequence amplification.
        Science. 1987; 273: 175
        • Leong A.S-Y.
        • Wright J.
        The contribution of immunohistochemical staining in tumor diagnosis.
        Histopathology. 1987; 11: 1295
        • Lilja H.
        A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.
        J Clin Invest. 1985; 76: 1899
        • Luthgens M.
        • Schlegel G.
        Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance.
        Cancer Detect Prev. 1983; 6: 52
      57. Luthgens M. Schlegel G. Tumor marker system CEA-TPA. Verlag, Stuttgart1987
        • Lydyard P.M.
        • Youinou P.Y.
        • Cooke A.
        CD5-positive B-cells in rheumatoid arthritis and chronic lymphocytic leukemia.
        Immunol Today. 1987; 8: 37
        • MacKenzie M.R.
        • Paglieroni T.G.
        • Warner N.L.
        Multiple myeloma: An immunologic profile. IV. The EA rosette-forming cell is a Leu-1 positive immunoregulatory B-cell.
        J Immunol. 1987; 139: 24
        • Magnani J.L.
        • Nilsson B.
        • Brockhaus M.
        • et al.
        A monoclonal antibody defined antigen associated with gastrointestinal cancer is a ganglioside containing sialyted lacto-N-fucopentaose II.
        J Biol Chem. 1982; 257: 14365
        • Mobus V.
        • Kreienberg R.
        • Crombach G.
        • et al.
        Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer.
        J Tumor Marker Oncol. 1988; 3: 251
        • Montinare F.
        • Beretta G.D.
        • Pancera G.
        • et al.
        CEA, TPA and CICA during long-term follow-up and in therapy monitoring of gastrointestinal tumors.
        J Tumor Marker Oncol. 1988; 3: 201
        • Moss K.B.
        • Wolfrum D.I.
        • Rauschrecker H.
        Determination of tissue polypeptide antigen (TPA) levels in different cancer types and controls.
        Oncology. 1985; 42: 288
        • Nap M.
        • Mollgard K.
        • Burtin P.
        • et al.
        Immunohistochemistry of carcinoembryonic antigen in embryo, fetus and adult.
        Tumor Biol. 1988; 9: 145
        • Nishimura S.
        • Sekiya T.
        Human cancer and cellular oncogenes.
        Biochem J. 1987; 243: 313
        • Nowell P.C.
        • Hungerford D.A.
        A minute chromosome in human chronic granulocytic leukemia.
        Science. 1960; 132: 1497
        • Orfao A.
        • Gonzalez M.
        • San Miguel J.F.
        • et al.
        B-cell chronic lymphocytic leukaemia: Prognostic value of the immunophenotype and the clinico-haematological features.
        Am J Hematol. 1989; 31: 26
        • Paglieroni T.
        • Caggiano V.
        • MacKenzie M.
        CD5 positive immunoregulatory B-cell subsets.
        Am J Hematol. 1988; 28: 276
        • Pastolero G.C.
        • Wakabayski T.
        • Oka T.
        • et al.
        Tissue polypeptide antigen-A marker antigen differentiating cholangiolar tumors from other hepatic tumors.
        Am J Clin Pathol. 1987; 87: 168
        • Paulick R.
        • Caffier H.
        • Horner G.
        • et al.
        Clinical significance of different serum tumor markers in gynecological malignancies.
        Cancer Detect Prev. 1985; 8: 115
        • Pavesi F.
        • Lotzniker M.
        • Marbello L.
        • et al.
        CA-125 in benign and malignant diseases involving coelomic epithelium.
        J Tumor Marker Oncol. 1988; 3: 49
        • Penn I.
        Tumor incidence in human allograft recipients.
        Trans Proc. 1979; 11: 1047
        • Perlin E.
        • Engeler J.E.
        • Edson M.
        • et al.
        The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors.
        Cancer. 1976; 37: 215
        • Persson B.E.
        • Stahle E.
        • Pahlman L.
        • et al.
        CA-50 as a tumor marker for monitoring colorectal cancer: Antigen rises in patients postoperatively precede clinical manifestations of recurrence.
        Eur J Cancer Clin Oncol. 1988; 24: 241
        • Pimentel E.
        Protooncogenes as human tumor markers.
        J Tumor Marker Oncol. 1986; 1: 27
        • Pohl A.
        Surveillance of cancer patients with tumor markers.
        J Tumor Marker Oncol. 1987; 2: 1
        • Pohl A.L.
        • Worofka B.
        • Dudczak R.
        • et al.
        Diagnostic efficacy of mutiple tumor markers in lung cancer.
        J Tumor Marker Oncol. 1988; 3: 387
        • Pons-Anicei D.
        • Ramaioli A.
        • Krebs B.P.
        • et al.
        CA 15-3: A prognostic factor for meta static breast cancer?.
        J Tumor Marker Oncol. 1988; 3: 159
        • Porter R.R.
        Chemical structure of γ-globulins and antibodies.
        Br Med Bull. 1963; 19: 197
        • Reddy E.P.
        • Reynolds R.K.
        • Santos E.
        • et al.
        A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.
        Nature (Lond). 1982; 300: 149
        • Reece E.R.
        • Gartner J.G.
        • Seemayer T.A.
        • et al.
        Epstein-Barr virus in a malignant lympho-proliferative disorder of B-cells occurring after thymic epithelial transplantation for combined immunodeficiency.
        Cancer Res. 1981; 41: 4243
      82. Reisfeld R. Sell S. Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, New York1985
        • Roland R.G.
        Serum markers in testicular neoplasms.
        Hematol Oncol Clin North Am. 1988; 2: 485
        • Rowley J.
        A new consistent chromosomal abnormality in chronic myelogenous leu kemia identified by quinacrine fluorescence and Giemsa staining.
        Nature (Lond). 1973; 243: 290
        • Ruther U.
        • Luthgens M.
        • Bader H.
        • et al.
        Human chorionic gonadotropin in patients with pure seminoma.
        J Tumor Marker Oncol. 1989; 4: 77
        • Safi F.
        • Beger H.G.
        • Bittner R.
        • et al.
        CA 19-9 and pancreatic adenocarcinoma.
        Cancer. 1986; 57: 779
        • Satake K.
        • Kanazawa G.
        • Kho I.
        • et al.
        A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
        J Surg Oncol. 1985; 29: 15
        • Schechter A.L.
        • Stern D.F.
        • Vaidyanathan L.
        • et al.
        The new oncogene: An erb-B related gene encoding a 180,000-Mr tumor antigen.
        Nature (Lond). 1984; 312: 513
        • Schultz H.
        • Sell A.
        • Norgaard-Pedersen B.
        • et al.
        Serum alpha-fetoprotein and human chorionic gonadotropin as markers for the effect of postoperative radiation therapy and/or chemotherapy in testicular cancer.
        Cancer. 1978; 42: 2182
        • Schuurman H.J.
        • Huppes W.
        • Verdonck L.F.
        • et al.
        Immunophenotyping of non-Hodg kin’s lymphoma, correlation with relapse-free survival.
        Am J Pathol. 1988; 131: 102
        • Schwartz B.R.
        • Pinkus G.
        • Bacus S.
        • et al.
        Cell proliferation in non-Hodgkin’s lym phomas. Digital image analysis of Ki-67 antibody staining.
        Am J Pathol. 1989; 134: 327
        • Seifert G.
        • Caselitz J.
        General aspects and diagnostic relevance of morphological tumor markers.
        J Tumor Marker Oncol. 1989; 4: 1
        • Sell S.
        Cancer Markers: Diagnostic and Developmental Significance. Humana Press, Clifton NJ1980
        • Sell S.
        Diagnostic applications of alpha-fetoprotein: Government regulations prevent full application of a clinically useful test.
        Human Pathol. 1981; 12: 959
      95. Sell S. Reisfeld R. Monoclonal Antibodies to Cancer. Humana Press, New York1985
        • Shapiro R.S.
        • Pietryga D.
        • Blazar B.R.
        • et al.
        B-cell lymphoproliferative disorders following bone marrow transplantation.
        Progress in Bone Marrow Transplantation. Alan R. Liss, New York1987: 647
        • Showe L.C.
        • Croce C.M.
        Oncogene probes in the detection of human cancer.
        Clin Physiol Biochem. 1987; 5: 227
        • Slamon D.J.
        • Clark G.M.
        • Wong S.G.
        • et al.
        Human breast cancer: Correlation of relapse and survival with amplification of HER-2/neu oncogene.
        Science. 1987; 235: 177
        • Slamon D.J.
        • Godolphin W.
        • Jones L.A.
        • et al.
        Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
        Science (USA). 1989; 244: 707
        • Soloman A.
        Homogeneous (monoclonal) immunoglobulins in cancer.
        Am J Med. 1977; 63: 169
        • Staab H.J.
        Medical and Biological Significance of Carcinoembryonic Antigen (CEA).
        Basel. F. Hoffman-La Roche Co, Switzerland1984
        • Stamey T.A.
        • Yang N.
        • Hay A.R.
        • et al.
        Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
        N Engl J Med. 1987; 317: 909
        • Stock L.M.
        • Brosman S.A.
        • Fahey J.L.
        • et al.
        Ras-related oncogene protein as a tumor marker in transitional cell carcinoma of the bladder.
        J Urol. 1987; 137: 789
        • Szpak C.A.
        • Johnson W.W.
        • et al.
        The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody.
        Am J Pathol. 1986; 122: 252
        • Tabin C.G.
        • Bardley S.M.
        • Bargmann C.I.
        • et al.
        Mechanism of activation of a human oncogene.
        Nature (Lond). 1982; 399: 143
        • Tanaka T.
        • Salmon D.J.
        • Shimoda H.
        • et al.
        Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient’s prognosis.
        Cancer Res. 1988; 48: 1030
        • Terry W.D.
        • Henkart P.A.
        • Coligan J.E.
        • et al.
        Carcinoembryonic antigen: Characteriza tion and clinical applications.
        Transplant Rev. 1974; 20: 100
        • Thompson J.
        • Zimmermann W.
        The carcinoembryonic gene family: Structure, expression and evolution.
        Tumor Biol. 1988; 9: 63
        • Tsuchida N.
        • Ryder T.
        • Ohtsubo E.
        Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten Murine Sarcoma Virus.
        Science. 1982; 217: 937
        • van de Vijver M.J.
        • Mooi W.J.
        • Peterse J.L.
        • et al.
        Amplification and overexpression of the neu gene in human breast carcinomas.
        Eur J Surg Oncol. 1988; 14: 111
        • van de Vijver M.J.
        • Peterse J.L.
        • Mooi W.J.
        • et al.
        Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
        N Engl J Med. 1988; 319: 1239
        • Varmus H.E.
        The molecular genetics of cellular oncogenes.
        Ann Rev Genet. 1984; 18: 553
        • Ventner D.J.
        • Tuzi L.
        • Kumar S.
        • et al.
        Overexpression of c-erb-2 oncoprotein in human breast carcinoma: Immunohistological assessment correlates with gene amplification.
        Lancet. 1987; 2: 69
        • Vogelzang N.J.
        • Lang P.H.
        • Goldman A.
        • et al.
        Acute changes of a-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
        Cancer Res. 1982; 42: 4855
        • Waldmann T.A.
        The arrangement of immunoglobulin and T-cell receptor genes in human lymphoproliferative disorders.
        Adv Immunol. 1987; 40: 247
        • Wang M.C.
        • Valenzuela L.A.
        • Murphy G.P.
        • et al.
        Purification of a human prostate specific antigen.
        Invest Urol. 1979; 17: 159
      117. Waterhouse J. Muir C. Shanmugaratnam K. Powell J. Cancer Incidence in Five Continents. World Health Organization, IARC Scientific Publishers, Lyon, France1982
        • Watt K.W.K.
        • Lee P.J.
        • M’Timkulu T.
        • et al.
        Human prostate specific antigen: Structure and functional similarity with serine proteases.
        Proc Natl Acad Sci USA. 1986; 83: 3166
        • Weber K.
        • Osborn M.
        • Moll R.
        • et al.
        Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8,18 and 19 typical of simple and non-squamous epithelia: Re-evaluation of a human tumor marker.
        EMBO. 1984; 3: 2702
        • Wolman S.R.
        • Henderson A.S.
        Chromosomal aberrations as markers of oncogene amplification.
        Human Pathol. 1989; 20: 309
        • Wright C.
        • Angus B.
        • Nicholson S.
        • et al.
        Expression of c-erb-2 oncoprotein: A prognos tic indicator in human breast cancer.
        Cancer Res. 1989; 49: 2087
        • Xu K.L.
        Large-scale AFP screening for hepatocellular carcinoma in China.
        in: Fishman W. Oncodevelopmental markers. Academic Press, San Diego1983
        • Yamamoto T.
        • Ikawa S.
        • Akiyama T.
        • et al.
        Similarity of protein encoded by the human c-erb B-2 gene to epidermal growth factor.
        Nature (Lond). 1980; 319: 230
        • Zamcheck N.
        Clinical use of carcinoembryonic antigen.
        Contr Oncol. 1981; 7: 25
        • Ziegler J.
        • Beckstead J.
        • Volberding P.
        • et al.
        Non-Hodgkin’s lymphoma in 90 homosexual men: Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome.
        N Engl J Med. 1984; 311: 565

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30580-8

      Copyright

      © 1990 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX